335 related articles for article (PubMed ID: 32456526)
1. MTHFD1L as a folate cycle enzyme correlates with prognostic outcome and its knockdown impairs cell invasive behaviors in osteosarcoma via mediating the AKT/mTOR pathway.
Wang L; Yang Y; Wang XM; Wang CQ; Zhang YM; Li BL
J Recept Signal Transduct Res; 2020 Dec; 40(6):584-590. PubMed ID: 32456526
[TBL] [Abstract][Full Text] [Related]
2. Arbutin suppresses osteosarcoma progression via miR-338-3p/MTHFD1L and inactivation of the AKT/mTOR pathway.
Wang CQ; Wang XM; Li BL; Zhang YM; Wang L
FEBS Open Bio; 2021 Jan; 11(1):289-299. PubMed ID: 33146000
[TBL] [Abstract][Full Text] [Related]
3. Integrated bioinformatics analysis identified MTHFD1L as a potential biomarker and correlated with immune infiltrates in hepatocellular carcinoma.
Chen J; Yang J; Xu Q; Wang Z; Wu J; Pan L; Huang K; Wang C
Biosci Rep; 2021 Feb; 41(2):. PubMed ID: 33605411
[TBL] [Abstract][Full Text] [Related]
4. Deletion of the neural tube defect-associated gene
Bryant JD; Sweeney SR; Sentandreu E; Shin M; Ipas H; Xhemalce B; Momb J; Tiziani S; Appling DR
J Biol Chem; 2018 Apr; 293(16):5821-5833. PubMed ID: 29483189
[TBL] [Abstract][Full Text] [Related]
5. Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma.
Lee D; Xu IM; Chiu DK; Lai RK; Tse AP; Lan Li L; Law CT; Tsang FH; Wei LL; Chan CY; Wong CM; Ng IO; Wong CC
J Clin Invest; 2017 May; 127(5):1856-1872. PubMed ID: 28394261
[TBL] [Abstract][Full Text] [Related]
6. Melatonin modulates metabolic remodeling in HNSCC by suppressing MTHFD1L-formate axis.
Cui L; Zhao X; Jin Z; Wang H; Yang SF; Hu S
J Pineal Res; 2021 Dec; 71(4):e12767. PubMed ID: 34533844
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial C1-tetrahydrofolate synthase (MTHFD1L) supports the flow of mitochondrial one-carbon units into the methyl cycle in embryos.
Pike ST; Rajendra R; Artzt K; Appling DR
J Biol Chem; 2010 Feb; 285(7):4612-20. PubMed ID: 19948730
[TBL] [Abstract][Full Text] [Related]
8. Integrative analysis reveals methylenetetrahydrofolate dehydrogenase 1-like as an independent shared diagnostic and prognostic biomarker in five different human cancers.
Sial N; Rehman JU; Saeed S; Ahmad M; Hameed Y; Atif M; Rehman A; Asif R; Ahmed H; Hussain MS; Khan MR; Ambreen A; Ambreen A
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34908119
[TBL] [Abstract][Full Text] [Related]
9. The role of mitochondrial folate enzyme MTHFD1L in esophageal squamous cell carcinoma.
Yang YS; Yuan Y; Hu WP; Shang QX; Chen LQ
Scand J Gastroenterol; 2018 May; 53(5):533-540. PubMed ID: 29171320
[TBL] [Abstract][Full Text] [Related]
10. miR-485-3p regulated by MALAT1 inhibits osteosarcoma glycolysis and metastasis by directly suppressing c-MET and AKT3/mTOR signalling.
Wang Q; Liu MJ; Bu J; Deng JL; Jiang BY; Jiang LD; He XJ
Life Sci; 2021 Mar; 268():118925. PubMed ID: 33358903
[TBL] [Abstract][Full Text] [Related]
11. Upregulated LEPRE1 correlates with poor outcome and its knockdown attenuates cells proliferation, migration and invasion in osteosarcoma.
Huang Z; Wang Q; Wang Y; Zhao L; Cao Z; Cui C; Yu D; Liu B
Anticancer Drugs; 2020 Apr; 31(4):326-332. PubMed ID: 32197005
[TBL] [Abstract][Full Text] [Related]
12. An NTD-associated polymorphism in the 3' UTR of MTHFD1L can affect disease risk by altering miRNA binding.
Minguzzi S; Selcuklu SD; Spillane C; Parle-McDermott A
Hum Mutat; 2014 Jan; 35(1):96-104. PubMed ID: 24123340
[TBL] [Abstract][Full Text] [Related]
13. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway.
Zheng J; Liu C; Shi J; Wen K; Wang X
Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34913077
[TBL] [Abstract][Full Text] [Related]
14. EEF1D overexpression promotes osteosarcoma cell proliferation by facilitating Akt-mTOR and Akt-bad signaling.
Cheng DD; Li SJ; Zhu B; Zhou SM; Yang QC
J Exp Clin Cancer Res; 2018 Mar; 37(1):50. PubMed ID: 29510727
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
[TBL] [Abstract][Full Text] [Related]
16. Deregulation of CLTC interacts with TFG, facilitating osteosarcoma via the TGF-beta and AKT/mTOR signaling pathways.
Shijie L; Zhen P; Kang Q; Hua G; Qingcheng Y; Dongdong C
Clin Transl Med; 2021 Jun; 11(6):e377. PubMed ID: 34185412
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of Ski decreases osteosarcoma cell proliferation and migration by suppressing the PI3K/Akt signaling pathway.
Zhao X; Fang Y; Wang X; Yang Z; Li D; Tian M; Kang P
Int J Oncol; 2020 Jan; 56(1):206-218. PubMed ID: 31746363
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of miR-122-5p regulating the activation of PI3K-Akt-mTOR signaling pathway on the cell proliferation and apoptosis of osteosarcoma cells through targeting TP53 gene.
Li KW; Wang SH; Wei X; Hou YZ; Li ZH
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12655-12666. PubMed ID: 33378012
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumoral potential of MDA19 in human osteosarcoma via suppressing PI3K/Akt/mTOR signaling pathway.
Liu B; Xu L; Dai EN; Tian JX; Li JM
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30442873
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of KRT17 decreases osteosarcoma cell proliferation and the Warburg effect via the AKT/mTOR/HIF1α pathway.
Yan X; Yang C; Hu W; Chen T; Wang Q; Pan F; Qiu B; Tang B
Oncol Rep; 2020 Jul; 44(1):103-114. PubMed ID: 32627037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
